Clinical Trial Update: Evaluating the Long-term Safety and Tolerability of Imatinib in Patients With Lymphangioleiomyomatosis (LAM) [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial update evaluating the long-term safety and tolerability of imatinib in patients with lymphangioleiomyomatosis (LAM) is currently recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphangioleiomyomatosis

Drugs mentioned

• Imatinib (imatinib)

Snippet

Sponsor: Columbia University | Conditions: Lymphangioleiomyomatosis (LAM), Lymphangioleiomyomatosis | Phase 1 | Status: RECRUITING